Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection.

ABSTRACT:

Introduction

Respiratory syncytial virus (RSV) is the single most important cause of severe respiratory illness in infants. There is no effective vaccine and the only effective treatment available is the monoclonal antibody palivizumab which reduces the risk of severe RSV disease in prematurely born infants. However, palivizumab is too costly to allow for wide implementation and thus treatment is restricted to supportive care. Despite extensive efforts to develop a vaccine, progress has been hindered by the difficulty in measuring and assessing immunological correlates of RSV vaccine efficacy in the presence of high levels of pre-existing RSV antibodies.

Methods

Here we describe a new method for measuring the functional activity of antibodies induced by vaccination distinct

SUBMITTER: Gerretsen HE 

PROVIDER: S-EPMC7116660 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature